DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome

被引:14
作者
Na, Joon Chae [1 ]
Nagaya, Naoya [2 ,3 ]
Rha, Koon Ho [1 ]
Han, Woong Kyu [1 ]
Kim, Isaac Yi [2 ,3 ]
机构
[1] Yonsei Univ, Coll Med, Urol Sci Inst, Dept Urol, 50 Yonsei Ro, Seoul 03722, South Korea
[2] Rutgers Canc Inst New Jersey, Sect Urol Oncol, New Brunswick, NJ USA
[3] Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA
关键词
ADJUVANT THERAPY; CANCER;
D O I
10.1016/j.clgc.2019.05.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We searched for a new therapeutic target for advanced clear-cell renal-cell carcinoma (ccRCC), the most common kidney cancer. The DNA damage response (DDR) pathway was investigated in 312 cases of localized ccRCC from The Cancer Genome Atlas database. Alterations in the DDR pathway are associated with increased recurrence in locally advanced ccRCC and may be a potential therapeutic target. Background: Advanced clear-cell renal-cell carcinoma (ccRCC), which is the most common subtype of kidney cancer, is considered to be lethal despite recent advancements in therapeutic agents. The benefit of adjuvant or neoadjuvant therapy with currently available agents remains controversial. We investigated the clinical implications of DNA damage response (DDR) pathway for locally advanced ccRCC. Patients and Methods: Localized ccRCC cases were selected from the Provisional TCGA (The Cancer Genome Atlas) database. Presence of mutation or copy-number alteration of DDR pathway-related genes were evaluated. Disease-free survival and overall survival according to disease progression were evaluated. Results: From TCGA database, 312 cases were identified of a localized ccRCC with full data on mutation and copy-number alteration. Alteration in the DDR pathway was present in 25.0% of cases. Female subjects were more likely to have alterations in the DDR pathway (34.6% vs. 48.7%, P = .026). DDR pathway alteration was associated with decreased disease-free survival in cases of locally advanced T3-4 disease (median, 123.7 vs. 23.0 months, T3 and T4 disease, P = .031). The association was more prominent in cases of T3a disease (normal group median not reached, altered group median 17.7 months, P < .001). DDR pathway alteration was an independent factor predicting a shorter disease-free survival on Cox regression analysis (odds ratio = 4.41; 95% confidence interval, 1.47 similar to 13.28; P = .008). Conclusion: Alteration in the DDR pathway was associated with increased recurrence in locally advanced ccRCC, and investigation of therapeutic agents targeting the DDR pathway for this population should be considered. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:299 / +
页数:8
相关论文
共 18 条
[1]   Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma [J].
Bex, Axel ;
Albiges, Laurence ;
Ljungberg, Borje ;
Bensalah, Karim ;
Dabestani, Saeed ;
Giles, Rachel H. ;
Hofmann, Fabian ;
Hora, Milan ;
Kuczyk, Markus A. ;
Lam, Thomas B. ;
Marconi, Lorenzo ;
Merseburger, Axel S. ;
Staehler, Michael ;
Volpe, Alessandro ;
Powles, Thomas .
EUROPEAN UROLOGY, 2017, 71 (05) :719-722
[2]   Neoadjuvant therapy for localized and locally advanced renal cell carcinoma [J].
Bindayi, Ahmet ;
Hamilton, Zachary A. ;
McDonald, Michelle L. ;
Yim, Kendrick ;
Millard, Frederick ;
McKay, Rana R. ;
Campbell, Steven C. ;
Rini, Brian I. ;
Derweesh, Ithaar H. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (01) :31-37
[3]   Renal cancer [J].
Capitanio, Umberto ;
Montorsi, Francesco .
LANCET, 2016, 387 (10021) :894-906
[4]   The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data [J].
Cerami, Ethan ;
Gao, Jianjiong ;
Dogrusoz, Ugur ;
Gross, Benjamin E. ;
Sumer, Selcuk Onur ;
Aksoy, Buelent Arman ;
Jacobsen, Anders ;
Byrne, Caitlin J. ;
Heuer, Michael L. ;
Larsson, Erik ;
Antipin, Yevgeniy ;
Reva, Boris ;
Goldberg, Arthur P. ;
Sander, Chris ;
Schultz, Nikolaus .
CANCER DISCOVERY, 2012, 2 (05) :401-404
[5]   Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma [J].
Chevinsky, Michael ;
Imnadze, Mariam ;
Sankin, Alexander ;
Winer, Andrew ;
Mano, Roy ;
Jakubowski, Christopher ;
Mashni, Joseph ;
Sjoberg, Daniel D. ;
Chen, Ying-Bei ;
Tickoo, Satish K. ;
Reuter, Victor E. ;
Hakimi, A. Ari ;
Russo, Paul .
JOURNAL OF UROLOGY, 2015, 194 (02) :310-315
[6]   Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal [J].
Gao, Jianjiong ;
Aksoy, Buelent Arman ;
Dogrusoz, Ugur ;
Dresdner, Gideon ;
Gross, Benjamin ;
Sumer, S. Onur ;
Sun, Yichao ;
Jacobsen, Anders ;
Sinha, Rileen ;
Larsson, Erik ;
Cerami, Ethan ;
Sander, Chris ;
Schultz, Nikolaus .
SCIENCE SIGNALING, 2013, 6 (269) :pl1
[7]   Does stage T3a renal cell carcinoma embrace a homogeneous group of patients? [J].
Gofrit, Ofer N. ;
Shapiro, Amos ;
Pizov, Galina ;
Landau, Ezekiel H. ;
Katz, Ran ;
Zorn, Kevin C. ;
Pode, Dov .
JOURNAL OF UROLOGY, 2007, 177 (05) :1682-1686
[8]   Targeting DNA damage response in cancer therapy [J].
Hosoya, Noriko ;
Miyagawa, Kiyoshi .
CANCER SCIENCE, 2014, 105 (04) :370-388
[9]   Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions [J].
Lalani, Aly-Khan A. ;
McGregor, Bradley A. ;
Albiges, Laurence ;
Choueiri, Toni K. ;
Motzer, Robert ;
Powles, Thomas ;
Wood, Christopher ;
Bex, Axel .
EUROPEAN UROLOGY, 2019, 75 (01) :100-110
[10]   Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials [J].
Lenis, Andrew T. ;
Donin, Nicholas M. ;
Johnson, David C. ;
Faiena, Izak ;
Salmasi, Amirali ;
Drakaki, Alexandra ;
Belldegrun, Arie ;
Pantuck, Allan ;
Chamie, Karim .
JOURNAL OF UROLOGY, 2018, 199 (01) :43-52